Invengene Private Limited has received regulatory approval for Parecoxib 40 mg injection in Zimbabwe, marking a key step in strengthening its presence across Africa and expanding access to hospital-based pain management therapies.

Parecoxib, a COX-2 inhibitor indicated for the management of post-operative pain, is widely used in acute care settings. With this approval, Invengene continues to build a focused portfolio of injectable products designed for reliability, scalability, and real-world clinical use.

This milestone reflects the company’s approach to developing formulations aligned with multi-market requirements from the outset, ensuring consistency in quality, regulatory compliance, and supply readiness.

Ankur Shah, Chairman & Managing Director, Invengene, said:
“This approval reflects our continued focus on building a portfolio that is relevant, scalable, and aligned with patient needs across markets. Expanding access to essential injectable therapies remains central to what we are building at Invengene.”

Invengene operates with an asset-light, globally integrated model, working with qualified manufacturing partners while maintaining strong oversight across development, regulatory strategy, and commercialisation.

The company continues to expand its injectable portfolio across emerging markets, including Africa, with a focus on improving access to high-quality, affordable therapies in regions where they are needed most.